Close

Abbott reports positive levodopa-carbidopa intestinal gel study data

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping

In the pharmaceutical industry, products frequently require very specific...

Litmys and PharmaACE Establish Strategic Partnership for Market Projections

Life sciences consulting firms Litmys and PharmaACE have officially...

Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate

Private equity firm Blackstone Life Sciences has agreed to...
- Advertisement -

Abbott has announced the Phase 3 study results of its levodopa-carbidopa intestinal gel (LCIG), used for the treatment of advanced Parkinson’s Disease (PD).

LCIG is administered via a procedurally-implanted tube connected to a portable pump which delivers the medication directly into the small intestine, providing a continuous delivery of medication during the 16 hours a day of pump use.

The 12-week double-blind double-dummy multi-site trial compared the efficacy, safety and tolerability of continuous LCIG infusion to standard levodopa-carbidopa immediate release (IR) tablets.

The study’s primary efficacy endpoint was change from baseline in daily off time (16 waking hours) at 12 weeks, and the secondary efficacy endpoint was change from baseline in daily on time which refers to periods of good motor symptom control without troublesome dyskinesias.

LCIG showed decrease in off time by 4 hours a day and increase in on time by 4.1 hours per day in the study. Mount Sinai School of Medicine, New York, US, Neurology and Neuroscience professor C.W. Olanow said the results demonstrated that continuous delivery of LCIG produces meaningful improvements in advanced PD patients by decreasing ‘off’ time and increasing ‘on’ time without troublesome dyskinetic symptoms.

“These benefits in a patient group that cannot be satisfactorily controlled with standard levodopa, represent an important step forward in our efforts to treat advanced PD patients,” Olanow added.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping

In the pharmaceutical industry, products frequently require very specific...

Litmys and PharmaACE Establish Strategic Partnership for Market Projections

Life sciences consulting firms Litmys and PharmaACE have officially...

Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate

Private equity firm Blackstone Life Sciences has agreed to...

How Biopharmaceutical Research Is Shaping the Future of Cancer Treatment

Cancer is no longer viewed solely as a clinical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »